Symbols

What is the long term forecast for LLY

6/5/2025 06:24pm

Aime

The deep research logic is organized as follows: 

Okay, let's tackle the user's question about the long-term forecast for Eli Lilly (LLY). The user is an investor interested in blue-chip stocks with a long-term horizon, so I need to focus on the company's fundamentals, growth prospects, and market position.

First, I'll check the provided references. The user mentioned LLY's financials, analyst ratings, and recent news. From the data, LLY has strong revenue and EPS growth rates. The 3-year CAGR for net income is 30.22%, revenue at 25.62%, and EPS at 30.27% . The latest Q1 2025 results show a 45.17% YoY revenue growth and 23.39% EPS growth . Analysts have a strong buy consensus with an average price target of $944.17 , and some even predict a $1 trillion market cap by 2027 .

The user is also interested in Buffett's holdings, so mentioning LLY's dominance in the weight loss market, which is a high-growth sector, might align with Buffett's preference for stable, cash-generating businesses. The partnership with Camurus for long-acting drugs  and the pipeline of new products like orforglipron  and retatrutide  could be key points. These innovations suggest LLY is well-positioned for future growth.

However, there's a downgrade from Erste Group to Hold , which might indicate some risks. The high P/E ratio (62x)  could be a concern, but the user's interest in long-term investments might overlook short-term volatility. The competition from Novo Nordisk  is another factor, but LLY's superior drug efficacy  gives them an edge.

I should structure the answer to highlight the bullish case first, then mention the risks. Use tables to present financial data clearly. Make sure to include the visualization for the LLY financials as per the user's instructions. Also, since the user likes blue-chip stocks, emphasizing LLY's market leadership and financial stability is crucial.

Need to ensure all data points are cited correctly and the answer flows logically from conclusion to detailed analysis. Keep the language professional but engaging, maybe add some emojis to make it lively as per the format requirements.

Conclusion 🌟

Eli Lilly (LLY) presents a compelling long-term investment opportunity driven by its dominance in the weight loss and diabetes markets, a robust pipeline of innovative drugs, and a strong financial foundation. However, the stock faces risks from high valuations, regulatory uncertainties, and competition. Below is a detailed analysis of LLY’s long-term prospects.

1. Financial Health & Growth Trajectory

LLY has demonstrated exceptional growth over the past three years, with:

Metric	3-Year CAGR (2022–2025Q1)
Net Income	30.22%
Revenue	25.62%
Diluted EPS	30.27%

Q1 2025 Highlights ¹:

Revenue: $12.73B (45.17% YoY growth)
Net Income: $2.76B (23.02% YoY growth)
Diluted EPS: $3.06 (23.39% YoY growth)

LLY’s 2025–2030 growth projections ² suggest continued dominance in the weight loss market, with tirzepatide-based drugs (Zepbound, Mounjaro) driving $58–$61B in annual revenue by 2025.

2. Market Position & Catalysts

Weight Loss Market Dominance

LLY controls ~35% market share in GLP-1 receptor agonists ³.
Zepbound (tirzepatide) achieved $4.93B in 2024 sales ⁴, with 350% YoY growth in Q1 2025 .
Mounjaro (diabetes treatment) generated $3.84B in 2024 sales ⁴, up 113% YoY .

Pipeline Innovations

Oroglipron (oral GLP-1 pill): Phase 3 success , targeting FDA approval in 2026 .
Retatrutide (triple GIP/GLP-1 agonist): Phase 3 data expected in 2025 , with potential superior efficacy over current treatments.
Camurus Partnership: Long-acting incretin therapies , enhancing LLY’s competitive edge in chronic disease management.

Regulatory & Expansion Catalysts

Kisunla (Alzheimer’s drug) approved in Australia ⁵.
Ovarian Cancer Drug (LY4170156): 55% response rate in Phase 1 ⁶⁷.

3. Analyst Consensus & Valuation

Price Targets

Metric	Value
Average Price Target	$944.17 (23.5% upside)
Bull Case	$1,190
Bear Case	$675

Valuation Risks

P/E Ratio: 62x (high relative to peers) .
Market Cap: ~$695B ³, raising concerns about valuation compression.

4. Risks & Competition

Competition

Novo Nordisk (NVO): Dominates GLP-1 market with 62% share .
Generic Threats: No immediate patent expirations ⁸, but FDA shortages (e.g., Zepbound) could impact supply ⁹.

Regulatory Risks

FDA Scrutiny: High-profile trials (e.g., retatrutide) face data-driven delays .
Litigation: Recent legal battles over drug shortages ⁹.

5. Long-Term Outlook

LLY is well-positioned to capitalize on the $381B weight loss market and $470B GLP-1 drug revenue ¹⁰ by 2030. With a $1 trillion market cap target and 26.81% upside potential , LLY offers a high-reward opportunity for long-term investors. However, caution is advised due to valuation risks and competitive pressures.

1/3

LLY Net Income YoY, Net Income

Source:

1. LLY Net Income, Revenue, Diluted EPS